Table 1. Demographics and patient characteristics (TKI treated, N=253).
| Characteristics | Number of patients (%) |
|---|---|
|
Age | |
| Median (range) | 65.2 years (26.2–95.5) |
|
Sex | |
| Female | 183 (72%) |
| Male | 70 (28%) |
|
Ethnicity | |
| White | 173 (59%) |
| Asian | 110 (38%) |
| Black | 10 (3%) |
| Median tumour sample cellularity (n=238) | 50.0% (range 1.0–98.0%) |
| Median EGFR mutation frequency (n=246) | 29.7% (range 0.4–96.2%) |
|
EGFR | |
| Exon 19 | 134 (53%) |
| Exon 21 | 119 (47%) |
|
Smoking history | |
| Current | 16 (7%) |
| Former | 80 (34%) |
| Non-smoker | 140 (59%) |
| Unknown | 17 |
|
Best response to EGFR TKI | |
| Response | 141(62%) |
| Stable/mixed | 58 (25%) |
| Progression | 30 (13%) |
| No assessment/unknown | 24 |
|
Sample tested | |
| Resected sample | 81 (32%) |
| Cytology sample | 76 (30%) |
| Core biopsy | 96 (38%) |
|
Biopsy site | |
| Primary | 154 (61%) |
| Metastases | 99 (39%) |
|
Received subsequent treatment after EGFR-TKI | |
| Second-line chemotherapy | 50 (20%) |
| Platinum-based doublet | 38 (15%) |
| Mean number of cycles of second-line chemotherapy | 4 cycles |
| Third line chemotherapy | 15 (6%) |
| Fourth line chemotherapy | 1 (0.3%) |
| Another EGFR TKI or TKI trial | 15 (6%) |
| Lost to follow-up | 27 (11%) |
Abbreviations: EGFR=epidermal growth factor receptor; TKI=tyrosine kinase inhibitor.